LOS ALTOS, Calif., March 25, 2024 (GLOBE NEWSWIRE) Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that multiple presentations will be delivered on the Company’s product candidates, oxylanthanum carbonate (OLC) and UNI-494, at the 61st European Renal Association (ERA) Congress taking place May 23-26, 2024, in Stockholm, Sweden. Shalabh Gupta, MD, Chief Execu
Hyperphosphatemia is the most common AE associated with FGFRi treatments and can impact patient quality of life, but there are treatments and possible diet changes that may help mitigate this AE.
On October 17, 2023, Ardelyx Inc announced the FDA approval of tenapanor (Xphozah) for reducing serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy.
“Finally!” Piper Sandler analysts cheered in a research note on Ardelyx Inc., which after spending three years battling the U.S. FDA, secured approval of Xphozah (tenapanor) for treating hyperphosphatemia in adults with chronic kidney disease (CKD). The company will waste no time getting to market, aiming to have the NHE3 inhibitor available to patients next month, marking the first new treatment class for hyperphosphatemia in 30 years.
MyJournals.org - Science - Prevalence and factors associated with hyperphosphatemia in continuous ambulatory peritoneal dialysis patients: A cross-sectional study (Frontiers in Medicine)